Stock Recommendation: Mirae Asset Sharkhan Suggests Buy For BSE

Mirae Asset Sharekhan Alternative Research Head Somil Mehta suggested a buy for BSE Ltd. The target price for the stock is Rs 2,950 apiece. The stop loss is at Rs 2,760 apiece.

Stock Recommendation: Macquarie On Tech Mahindra

  • Maintain Underperform; Hike target price to Rs 1,090 from Rs 1,050

  • 15% EBIT margin target by FY27E a very tough ask

  • Years of underinvestment in sectors outside Telecom a tough fix

  • Incumbency a disadvantage for TechM with Telecom clients

  • 15% EBIT margin goal a tough ask, we expect only 12.5-13.5% is achievable

  • Add Tech Mahindra to Macquarie Marquee Sell ideas

  • See LTIMindtree as far more attractively positioned

Stock Market Today: Buy Aurobindo Pharma With Target Price Rs 1,240 

Religare Broking Research Senior Vice President Ajit Mishra suggested a buy Aurobindo Pharma Ltd. The target price is at Rs 1,240 apiece. The stop loss is at Rs 1,110 apiece.

Stock Market Live: MS On Marico 

  • Maintain Equal-weight with TP of Rs 674

  • First quarter: Top-line Growth +20%; VAHO Saw Strong Recovery

  • Demand trends were consistent with improving rural and steady urban

  • Domestic volume growth continues to see sequential improvement

  • Gross margin to remain under incremental pressure

Stock Recommendation: InCred On E2E Network

  • Initiate Add with a target price of Rs 3,245.

  • E2E is at the trifecta of AI, infrastructure and software platform opportunity

  • Leading self-service cloud GPU provider at scale

  • Predictable & affordable pricing, and parentage-led B/S strength provides an early mover advantage

  • Software – critical to unlock infrastructure price performance

  • See revenue/EBITDA CAGR of ~60% over FY25-28F driven by monetization of capacity addition and accelerating adoption

Stock Recommendation: Angel One Suggests Buy For Natco Pharma 

Angel One Research Senior Vice President suggested a buy for Natco Pharma. The target price is at Rs 1,057. The stop loss is at Rs 917 apiece.

Stock Recommendation: Mehta Equities Suggests Buy For Strides Pharma 

Mehta Equities Research Vice President Prashanth Tapse suggested a buy for Strides Pharma Science Ltd. The analyst remains positive about the pharmaceutical sector, expecting positive outcomes from the India–US agreement. Although Strides Pharma has limited presence in the US, its current valuation makes it an appealing investment opportunity.

. Read more on Markets by NDTV Profit.Disclaimer: The views and opinions expressed by the investment advisers are of their own and not of NDTV Profit. NDTV Profit advises readers to consult their financial advisers before investment.  Read MoreMarkets, Business, Notifications 

​NDTV Profit